Regeneron Pharmaceuticals (REGN) just picked up an important regulatory win in Japan, where health authorities approved Dupixent for children aged 6 to 11 with severe bronchial asthma, widening the ...
Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it failed to meet efficacy expectations. In a statement, J&J said that ...
Dec 26 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate to severe atopic dermatitis after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results